by synergycap1 | Mar 29, 2017 | Bad Credit Loans, Bank Lending, Bureau of Labor Statistics, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
The nation’s top military official in the Middle East on Wednesday said Iran is one of the greatest threats to the U.S. today and has increased its “destabilizing role” in the region. “I believe that Iran is operating in what I call a gray...
by synergycap1 | Mar 29, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Finance, Non-Bank Loans, Working Capital
PRESCOTT, Ont. – Prescott Mayor Brett Todd wants trucks carrying hazardous materials to be banned from Hwy. 401 during storms, local media reports. The call for a ban comes after a deadly crash earlier this month during a snowstorm. “Why…
by synergycap1 | Mar 29, 2017 | Bad Credit Loans, Bank Lending, Business Loans, Capital, Non-Bank Loans, Working Capital
Paper wealth is meaningless when it comes to true financial security. Or, more accurately, there’s an enormous difference between paper wealth and real wealth. With investments, until you sell an asset and lock in any gains you have (hopefully) accrued, all you...
by synergycap1 | Mar 29, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Working Capital
Securing a contract to manage a Fortune 500 company’s local distribution center, XPO Logistics Supply Chain maintained its No. 1 spot on Memphis Business Journal’s annual Third-Party Distribution Operations list. The list ranks companies by local warehouse...
by synergycap1 | Mar 29, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Finance, Working Capital
March 29, 2017 By PUI-WING TAM Journalists at The New York Times use technology in weird and wonderful ways. Mostly weird ways, it turns out, in the case of Farhad Manjoo, The Times’s technology columnist. This year, we have been profiling how Times journalists...
by synergycap1 | Mar 29, 2017 | Bad Credit Loans, Bank Lending, Bureau of Labor Statistics, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Mylan said on Wednesday its application to market a generic copy of GlaxoSmithKline’s blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration. Mylan’s shares fell nearly 2 percent to $40.90 in afternoon trading. The FDA...
